**PARTICIPANT INFORMATION SHEET**

**Take Home Naloxone (THN) Pilot Evaluation – Naloxone Distribution Data**

---

**Project Title**  
Evaluation of the Pharmaceutical Benefits Scheme Subsidised Take Home Naloxone Pilot

**Ethics Approval Number**  
2019002505

**Project Sponsor**  
Commonwealth Department of Health

**Evaluation Lead**  
Dr Caroline Salom

**Evaluation Associate Investigators**  
Professor Lisa McDaid, Dr Amy Peacock, Dr Natasa Gisev, Dr Joemer Maravilla, Dr Jennifer Juckel, Catherine Daly, Professor Michael Farrell, and Associate Professor Raimondo Bruno

---

**Why have I been asked for permission to use my information?**

The Commonwealth Department of Health is trialing a scheme for the provision of free Take Home Naloxone (THN) to people who may be at risk of experiencing an opioid overdose or who may witness an opioid overdose. This scheme is called the Pharmaceutical Benefits Scheme Subsidised Take Home Naloxone Pilot.

You have chosen to take advantage of this THN pilot. We are asking for permission to use your information to help evaluate this pilot.

---

**What is the Evaluation of the Pharmaceutical Benefits Scheme Subsidised Take Home Naloxone Pilot?**

The Commonwealth Government’s THN pilot aims to increase the availability of and access to naloxone for at-risk groups, including people who are at risk of experiencing or witnessing an opioid overdose as well as their families and communities. The THN pilot will provide naloxone free of charge, with brief training on appropriate use, across a range of sites in New South Wales, South Australia and Western Australia. This has the potential to reduce the rate of opioid-related deaths among specified target populations.

---

**What is the purpose of the information collection?**

We are collecting data at the point where people collect their THN to help us understand how many people (and which groups) are participating in the Pilot, which forms of THN they are collecting and how often, whether they have been offered advice or education on how to use the THN, and whether the THN has been used to resuscitate someone.

---

**What does providing my information require?**

You just need to provide a verbal consent for your information to be used. You do not have to give your name.

---

**Are there any risks involved in participating?**

There is no physical risk associated with participating. We do not expect that providing your information will cause you any significant distress. However, there is a small risk that thinking about your experiences may cause you distress. Should you experience any distress as you collect your THN, we recommend you speak to a trained counsellor at Lifeline by calling 13 11 14 or via https://www.lifeline.org.au
Do I have to provide my information?

Your participation is voluntary, and you are not obliged to allow your information to be used. You can choose not to provide some information if you wish, and you can withdraw your consent and discontinue participation at any time without any comment or penalty.

What are the possible benefits of participation?

Although you won’t gain any direct benefits from providing your information, it will however, help us to understand how the THN Pilot is progressing, and inform future programs to support provision of THN to people for whom it will be most helpful.

Will the information you give be confidential?

Your information will remain confidential and anonymous. Your name will not be recorded anywhere. Your information will only be viewed by the evaluation team. Although we will report on the overall findings, we will not identify any individuals in our reports, only collated data for the purpose of describing the findings. We will not share any individual information with organisations involved in the THN Pilot.

Limits of confidentiality – illegal activity

By providing your verbal consent, you consent to the evaluation team collecting and using information about you for the evaluation. Information you provide us with will remain confidential and will be disclosed only with your permission, except where as required by law. However, any serious or imminent threat to harm yourself or others may have to be reported to another person (the project leader in the first instance), and any information regarding the protective safety of children will be reported to relevant authorities.

What should I do if I have further questions about my involvement in the evaluation?

You are free to discuss your participation with the evaluation team: you may call the principal investigator, Dr Caroline Salom on (07) 3346 7695. If you would like to speak to an officer of the University not involved in the evaluation, you may contact the Ethics Coordinators on (07) 3365 3924 or (07) 3443 1654 or email humanethics@research.uq.edu.au. If you would like a copy of the evaluation findings please contact UQ ISSR (naloxone.issr@uq.edu.au).

This study adheres to the Guidelines of the ethical review process of The University of Queensland and the National Statement on Ethical Conduct in Human Research. The confidentiality of all evaluation related records will be maintained in accordance with the Australian National Health and Medical Research Council (NHMRC) guidelines. The University of Queensland’s Human Research Ethics Committee (HREC) has reviewed and approved this information sheet and consent form.